New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For A;R;SPW;SNY;WBMD;CVS;ESV;TER;BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
March 5, 2015
07:20 EDTRJPMorgan to hold a conference
Aviation, Transportation & Industrials Conference is being held in New York on March 3-5 with webcasted company presentations to begin on March 5 at 8 am; not all company presentations may be webcasted. Webcast Link
March 4, 2015
11:09 EDTSNYSanofi, Novartis, Shire may be weighing Genfit acquisition, Bloomberg says
Subscribe for More Information
07:12 EDTRJPMorgan to hold a conference
Subscribe for More Information
March 3, 2015
11:46 EDTSNYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
08:02 EDTBSXBoston Scientific acquisition positive, says Wells Fargo
Subscribe for More Information
07:56 EDTBSXBoston Scientific remains a top pick at JPMorgan
Subscribe for More Information
March 2, 2015
16:26 EDTBSXOn The Fly: Closing Wrap
Subscribe for More Information
12:13 EDTBSXOn The Fly: Midday Wrap
Subscribe for More Information
10:00 EDTESVOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:53 EDTSNYNon-profit gives lukewarm review to MannKind inhaled insulin, TheStreet says
Subscribe for More Information
08:27 EDTESVEnsco downgraded to Underperform from Market Perform at BMO Capital
BMO Capital downgraded Ensco to Underperform and said Offshore Drillers appear to be in a secular downturn and bounces should be sold.
07:16 EDTBSXEndo to divest AMS men's and prostate health businesses to Boston Scientific
Endo International (ENDP) announced it has entered into a definitive agreement with Boston Scientific (BSX), under which Boston Scientific will acquire Endo's American Medical Systems' Men's and Prostate Health businesses for up to $1.65B, with $1.6B in cash payable at closing. Endo is also eligible to receive a potential milestone payment of $50M in cash conditioned on Boston Scientific achieving certain product revenue milestones in the Men's Health and Prostate Health businesses in 2016. In addition, Endo is currently evaluating strategic alternatives for the AMS Women's Health business. The transaction is expected to close in the third quarter of 2015, subject to customary conditions, including the expiration or termination of any applicable waiting periods under applicable competition laws. Endo will classify and report results of AMS as Discontinued Operations. FY15 Endo guidance will be provided on a continuing operations basis.
07:10 EDTBSXEndo to sell AMS urology portfolio to Boston Scientific for up to $1.65B
Boston Scientific (BSX) announced that it has entered into a definitive agreement with Endo International (ENDP) to acquire the American Medical Systems' urology portfolio, which includes the Men's Health and Prostate Health businesses, for $1.6B in up-front cash and a potential additional $50M milestone based on 2016 sales. The company expects to close the transaction in the third quarter of 2015, subject to customary closing conditions. Upon completion of the transaction, the AMS Men's Health and Prostate Health businesses will become part of Boston Scientific Urology and Women's Health. The acquisition encompasses the AMS product portfolio for treating urologic conditions, including benign prostatic hyperplasia, male stress urinary incontinence and erectile dysfunction. These technologies complement Boston Scientific's strong kidney stone, pelvic organ prolapse, female stress urinary incontinence and abnormal uterine bleeding treatment portfolios, and together, will provide customers with a comprehensive urology, urogynecology and gynecologic surgery portfolio. The AMS women's health business for treating pelvic organ prolapse and female stress urinary incontinence is not included in the transaction. The AMS Men's Health and Prostate Health businesses generated 2014 sales of approximately $400M and adjusted operating income of approximately $130M, excluding amortization and certain allocated expenses. GAAP operating income, including amortization and certain allocated expenses, was approximately $60M in 2014. The acquisition is expected to result in annual pre-tax synergies in excess of $50M by the end of 2018. On an adjusted basis, the transaction is expected to be breakeven to adjusted earnings per share in 2015, accretive by at least 3c in 2016, approximately 7c in 2017, and increasingly accretive thereafter. The transaction is expected to be less accretive, or dilutive, as the case may be, on a GAAP basis 2015 through 2017, due to amortization expense and transaction and integration costs. The acquisition is being structured as an asset purchase for tax purposes. Boston Scientific intends to finance the acquisition through a combination of existing and newly committed credit facilities.
07:08 EDTBSXEndo to sell AMS urology portfolio to Boston Scientific for up to $1.65B
Subscribe for More Information
07:08 EDTBSXBoston Scientific enters $1.65B agreement with Endo to acquire urology portfolio
Subscribe for More Information
February 27, 2015
09:53 EDTESVEnsco pullback overdone, says Evercore ISI
Evercore ISI said the pullback in Ensco following the Q4 report is overdone. The firm said the risk of dividend cut was well telegraphed and yesterday's weakness was magnified by price weakness in oil. The firm maintains its Buy rating and said Ensco is prudent in managing cash flow for a multi-year down-cycle and will be well positioned to take advantage of opportunities to upgrade the fleet.
07:22 EDTSNYSanofi reports positive opinion from CHMP for Toujeo
Sanofi announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has issued a positive opinion recommending the approval of Toujeo, a next-generation basal insulin for the treatment of adults with type 1 and type 2 diabetes. Toujeo has demonstrated a more stable and a prolonged glycemic control that lasts beyond 24 hours compared with Lantus with low within-individual, within-day blood sugar variability. The European Commission is expected to make a final decision on granting marketing authorization for Toujeo in the EU in the coming months. Toujeo was approved by the FDA and is under review by other regulatory authorities around the world. Once approved, Toujeo will be available in the Toujeo SoloSTAR, a disposable prefilled pen which contains 450 insulin units, and it has a maximum single injection dose of 80 IU.
February 26, 2015
15:30 EDTESVNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Monster Beverage (MNST), consensus 59c... Ross Stores (ROST), consensus $1.11... Gap (GPS), consensus 74c... Autodesk (ADSK), consensus 24c... Universal Health Services (UHS), consensus $1.50... Southwestern Energy (SWN), consensus 50c... Ensco (ESV), consensus $1.36... J.C. Penney (JCP), consensus 11c... Nimble Storage (NMBL), consensus (14c)... Herbalife (HLF), consensus $1.22... Allscripts Healthcare (MDRX), consensus 9c... SBA Communications (SBAC), consensus 2c... Aruba Networks (ARUN), consensus 27c... Splunk (SPLK), consensus 4c... Air Lease (AL), consensus 61c... Ingram Micro (IM), consensus 99c... Weight Watchers (WTW), consensus 7c... Northern Oil and Gas (NOG), consensus 19c... Envision Healthcare (EVHC), consensus 36c... Infoblox (BLOX), consensus 5c... Live Nation (LYV), consensus (41c)... OmniVision (OVTI), consensus 29c... Bonanza Creek Energy (BCEI), consensus 27c.
11:42 EDTESVEnsco says not giving FY15 revenue outlook due to lack of visibility
Subscribe for More Information
11:37 EDTESVEnsco sees Q1 revenue to decline 'slightly' from Q4
Subscribe for More Information
05:40 EDTESVEnsco reports Q4 EPS ($14.89), may not compare to consensus $1.36
Reports Q4 revenue $1.16B, consensus $1.16B. The loss from continuing operations in Q4 was $13.22 per share, compared to earnings of $1.70 per share a year ago. The loss from discontinued operations in Q4 was $1.67 per share compared to a loss of 16c per share the prior year. The loss of $14.89 per diluted share in Q4 compared to earnings of $1.54 per diluted share in 4Q13.
05:32 EDTSNYSanofi receives FDA approval of once-daily basal insulin Toujeo
Sanofi announced that the FDA approved Toujeo, a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2. The approval of Toujeo was based on FDA review of results from the EDITION clinical trial program, which was comprised of a series of international Phase III studies evaluating the efficacy and safety of Toujeo in more than 3,500 adults from broad and diverse diabetes populations.
February 25, 2015
20:05 EDTSNYSanofi receives FDA approval of once-daily basal insulin Toujeo
Subscribe for More Information
10:01 EDTAOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:28 EDTAAgilent upgraded to Buy from Neutral at BTIG
Subscribe for More Information
08:11 EDTSPWSPX Corp. selected by Arla Foods for processing systems at UK dairy plant
Subscribe for More Information
07:55 EDTRNational Tube Supply renews contract with Ryder
Ryder System announced that National Tube Supply, a national distributor of carbon and alloy mechanical tubing, has renewed its contract for dedicated transportation services with Ryder.
07:18 EDTAG Corp to hold annual meeting
Subscribe for More Information
February 24, 2015
16:08 EDTWBMDWebMD sees FY15 net income approximately $50.5M-$59.5M, consensus $1.21
Sees FY15 revenue approximately $615M-$635M, consensus $634.89M. Adjusted EBITDA to be approximately $180M-$190M, an increase of approximately 13%-20% from the prior year.
16:06 EDTWBMDWebMD sees Q1 net income approximately $8.5M-$9.5M, consensus 22c
Subscribe for More Information
16:05 EDTWBMDWebMD reports traffic during Q4 reached 190M unique users per month
Traffic to the WebMD Health Network during the fourth quarter reached an average of 190M unique users per month generating 3.7B page views for the quarter, increases of 22% and 17%, respectively, from the prior year period.
16:04 EDTWBMDWebMD reports Q4 adjusted EPS 36c, consensus 32c
Subscribe for More Information
14:31 EDTBSXBoston Scientific deal for Endo unit would be favorably received, says Needham
Subscribe for More Information
13:23 EDTCVSLeerink healthcare technology analyst holds analyst/industry conference call
Healthcare Tech & Distribution Analyst Larsen discusses th 2016 Pharmacy Benefits Management (PBM) selling season, the impact of the Hep C PBM formulary negotiations on the selling season and specialty drug trend and areas of opportunity for PBMs on an Analyst/Industry conference call to be held on March 5 at 2 pm.
12:40 EDTBSXBoston Scientific may strike deal for Endo AMS unit within weeks, Reuters says
Boston Scientific (BSX) is reportedly close to buying Endo International's (ENDP) AMS medical device unit which could be valued at roughly $2B, reports Reuters, citing people familiar with the matter. The sources said the companies want to finalize a deal "within a matter of weeks" but cautioned that talks are continuing and could still fail. Reference Link
12:14 EDTBSXEndo near deal to sell AMS device unit to Boston Scientific, Reuters says
February 23, 2015
14:51 EDTWBMDWebMD volatility elevated into Q4 and outlook
Subscribe for More Information
February 20, 2015
07:08 EDTSNY, BSXAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use